![Quiver Logo](/static/img/logo-icon.png)
![RAPP logo](https://quiver-logos.s3.us-east-2.amazonaws.com/rapp.png)
Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view RAPP Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of RAPP by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by RAPP's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to RAPP
Recent picks made for RAPP stock on CNBC
ETFs with the largest estimated holdings in RAPP
Flights by private jets registered to RAPP
![Quiver Logo](/static/img/logo-icon.png)